Hand fan to prevent ticagrelor-related breathlessness
Effect of Fan Application in Preventing Ticagrelor-associated Dyspnea in Patients With Acute Coronary Syndrome.
This study will try to see if using a handheld fan can reduce breathing discomfort in adults with acute coronary syndrome who are starting ticagrelor.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 110 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Acibadem University Academic / other |
| Locations | 2 sites (Istanbul, Avcılar and 1 other locations) |
| Trial ID | NCT07268859 on ClinicalTrials.gov |
What this trial studies
This randomized, controlled study will enroll 110 patients admitted to coronary intensive care units in Istanbul who are initiating ticagrelor. Participants will be randomly assigned to standard care or standard care plus regular hand fan therapy and will be monitored for ticagrelor-associated dyspnea. The intervention is unblinded for patients and the researcher, while data analysis will be performed by an independent statistician. Outcomes will compare dyspnea frequency and severity between groups to determine whether the nonpharmacological fan intervention provides symptom relief.
Who should consider this trial
Good fit: Adults aged 18–65 with a first episode of acute coronary syndrome, able to communicate in Turkish and starting ticagrelor, are ideal candidates.
Not a fit: Patients with major respiratory diseases, cognitive or communication impairments, prior ticagrelor use, or those who are intubated are excluded and unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, the hand fan could offer a simple, low-cost way to reduce ticagrelor-related breathlessness for patients.
How similar studies have performed: Hand-held fan therapy has reduced dyspnea in other conditions such as COPD and palliative care, but its use specifically for ticagrelor-associated dyspnea is novel and not previously established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Between the ages of 18 and 65, * No severe hearing and vision problems, * Can speak and understand Turkish, * Easy to communicate with, * First-time sufferer of acute coronary syndrome (ACS) for the first time, * Decided to start ticagrelor therapy, * Able to adapt to treatment, * Individuals who volunteered to participate in the research. Exclusion Criteria: * Having any problem that prevents you from communicating cognitively, emotionally and verbally, * Obstructive sleep abnormalities, * Have a disease that affects respiratory function (stage IV cancer, bronchial asthma, COVID-19, lung cancer, pulmonary edema, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism, pneumonia or bronchitis, etc.), * With metabolic abnormalities, * Intubated after the procedure, * Previously treated with ticagrelor, * Individuals who did not volunteer to participate in the study. Losses to follow up * Individuals who wish to leave the study voluntarily. * Saturation value below 95%, * The one with the arrest, * Who will not be able to fulfill the requirements of the work, * Individuals with life-threatening conditions
Where this trial is running
Istanbul, Avcılar and 1 other locations
- İstanbul Üniversitesi-Cerrahapaşa — Istanbul, Avcılar, Turkey (Türkiye) (Not_yet_recruiting)
- Sağlık Bilimleri Üniversitesi Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Eğitim Araştırma Hastanesi — Istanbul, Üsküdar, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Emine Tuğba YORULMAZ, research assistant
- Email: tugbayoorlmz@gmail.com
- Phone: +905556177281
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.